Pneumotox » Drug » Sacituzumab (govitecan) » XXI.e - Rechallenge may not necessarily lead to relapse of AE/ILD

Sacituzumab (govitecan)

See Cruse A et al. A case of sacituzumab-induced pneumonitis. Chest 2023; 164 (45): 3316A

Last update : 11/04/2025

Diagnosing DIRD

Drug and radiation history

Drug singularity - Correct identification of the drug

Consistent timing of exposure v. onset of symptoms

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

Careful exlusion of another cause

Remission of symptoms with removal of drug

Recurrence with rechallenge (rarely advisable)

Causality assessment